The radiopharmaceutical field is one of the hottest areas in cancer treatment, and there has been something of a scramble recently with several major deals. The latest, only a couple of days old, is Australian Telix’s acquisition of German ITM, creating a new major player in the field, as Life Science Focus previously reported.
Novartis makes a move in red‑hot radiopharma space
Novartis is expanding its radiopharmaceutical pipeline through a licensing agreement with Chinese BoomRay Therapeutics worth up to 900 million dollars.
Advertisement
BREAKING